GenLab: Unveiling the Genetic Landscape of Brugada Syndrome: Novel Biomarker Discovery for Precise Diagnosis

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorIRCCS Policlinico S. Donato

About this trial

This research makes several significant contributions to the field of BrS. It employs advanced genetic sequencing techniques to develop a genetic signature to improve the accuracy and efficiency of BrS diagnosis. The identification of specific biomolecular profiles and genetic signatures enhances our understanding of the syndrome's molecular mechanisms, facilitating targeted therapies and refined risk stratification. These advancements optimize patient care by enabling personalized treatment plans and risk assessment. Overall, this research adds value by advancing diagnostic methods, providing molecular insights, optimizing patient care, and positively impacting public health outcomes in BrS.

Eligibility criteria

Qualifiers

Age > 18 years

Patients affected by Brugada Syndrome

Patients who signs the Informed Consent

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

350 Participants
are grouped into 1 trial group

Sponsors and collaborators

IRCCS Policlinico S. Donato

Lead sponsor

Azienda Ospedaliero Universitaria di Sassari

Collaborator

The National Research Council, Italy

Collaborator